Can a simple CT scan catch lung cancer early in indian smokers?
NCT ID NCT07590440
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will check if low-dose CT scans can find lung cancer early in 1,716 high-risk smokers in India. Participants get a baseline scan, and if anything looks suspicious, they are referred to a team of specialists for follow-up. The goal is to see if this screening method works well in the Indian population and to improve how lung cancer care is delivered.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- low-dose CT scan
- What this could lead to
- If successful, this could show that low-dose CT screening effectively catches lung cancer early in high-risk Indian smokers, potentially saving lives through timely treatment.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly cure or treat cancer. Results may not apply to all populations, and false positives could cause unnecessary stress or procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,716 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Individuals with a history of smoking at least 20 pack-years * either current smokers or those who quit within the last 15 years Exclusion Criteria: * Person who smoked fewer than 100 cigarettes in their lifetime * individuals currently receiving treatment for active cancer
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dr Bhimrao Ambedkar Institute Rotary Cancer Hospital, AIIMS, New Delhi, India
Delhi, National Capital Territory of Delhi, 110029, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?
- Amazon plant put to the test against Cancer's relentless tiredness
- Can a virtual stress program help working spouses care for cancer patients without burning out?
- Freezing probe aims to kill lung tumors through the airways